CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the issuance of US patent 7,262,286 (the ‘286 patent) for novel immunostimulatory oligonucleotide compositions. The claims of this patent, entitled “Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs By Positional Chemical Changes” cover oligonucleotide compounds comprising a synthetic immunostimulatory dinucleotide motif. The claimed dinucleotide motifs contain certain analogs of cytosine together with guanosine or certain analogs of guanosine.
